Teva (TEVA) Hits Session Lows as Biogen (BIIB) MS Pill Gains Approval
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Shares of Teva (NYSE: TEVA) declined late on Wednesday after news broke that the FDA approved Biogen's (Nasdaq: BIIB) Tecfidera (dimethyl fumarate) capsules to treat adults with relapsing forms of multiple sclerosis (MS).
Shares of Teva are lower by over 1 percent.
Shares of Teva are lower by over 1 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
- Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
